Vaccibody is now public company listed on Euronext Merkur
VACCIBODY ENTERS INTO WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH GENENTECH, A MEMBER OF THE ROCHE GROUP, TO DEVELOP INDIVIDUALIZED NEOANTIGEN CANCER VACCINES
Vaccibody enters into worldwide, exclusive license and collaboration agreement with Genentech to develop VB10.NEO, individualized neoantigen cancer vaccines
OCTOBER 1, 2020
VACCIBODY LISTS ON OSLO STOCK EXCHANGE’S MERKUR MARKET
Vaccibody Lists on Oslo Stock Exchange’s Merkur Market
OCTOBER 7, 2020
Vaccibody enters into worldwide, exclusive license and collaboration agreement with Genentech to develop VB10.NEO, individualized neoantigen cancer vaccines
OCTOBER 1, 2020
VACCIBODY LISTS ON OSLO STOCK EXCHANGE’S MERKUR MARKET
Vaccibody Lists on Oslo Stock Exchange’s Merkur Market
OCTOBER 7, 2020
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.